T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

Donald R. Shaffer, Barbara Savoldo, Zhongzhen Yi, Kevin K.H. Chow, Sunitha Kakarla, David M. Spencer, Gianpietro Dotti, Meng Fen Wu, Hao Liu, Shannon Kenney, Stephen Gottschalk

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

T-cell therapy with genetically modified T cells targeting CD19 or CD20 holds promise for the immunotherapy of hematologic malignancies. These targets, however, are only present on B cell-derived malignancies, and because they are broadly expressed in the hematopoietic system, their targeting may have unwanted consequences. To expand T-cell therapies to hematologic malignancies that are not B cell-derived, we determined whether T cells can be redirected to CD70, an antigen expressed by limited subsets of normal lymphocytes and dendritic cells, but aberrantly expressed by a broad range of hematologic malignancies and some solid tumors. To generate CD70-specific T cells, we constructed a chimeric antigen receptor (CAR) consisting of the CD70 receptor (CD27) fused to the CD3-ξ chain. Stimulation of T cells expressing CD70-specific CARs resulted in CD27 costimulation and recognition of CD70-positive tumor cell lines and primary tumor cells, as shown by IFN-γ and IL-2 secretion and by tumor cell killing. Adoptively transferred CD70-specific T cells induced sustained regression of established murine xenografts. Therefore, CD70-specific T cells may be a promising immunotherapeutic approach for CD70-positive malignancies.

Original languageEnglish (US)
Pages (from-to)4304-4314
Number of pages11
JournalBlood
Volume117
Issue number16
DOIs
StatePublished - Apr 21 2011
Externally publishedYes

Fingerprint

T-cells
Immunotherapy
T-Lymphocytes
Cells
Tumors
Neoplasms
Hematologic Neoplasms
Cell- and Tissue-Based Therapy
CD70 Antigens
B-Lymphocytes
Hematopoietic System
Antigen Receptors
Lymphocytes
Lymphocyte Subsets
Tumor Cell Line
Heterografts
Dendritic Cells
Interleukin-2

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., ... Gottschalk, S. (2011). T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood, 117(16), 4304-4314. https://doi.org/10.1182/blood-2010-04-278218

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. / Shaffer, Donald R.; Savoldo, Barbara; Yi, Zhongzhen; Chow, Kevin K.H.; Kakarla, Sunitha; Spencer, David M.; Dotti, Gianpietro; Wu, Meng Fen; Liu, Hao; Kenney, Shannon; Gottschalk, Stephen.

In: Blood, Vol. 117, No. 16, 21.04.2011, p. 4304-4314.

Research output: Contribution to journalArticle

Shaffer, DR, Savoldo, B, Yi, Z, Chow, KKH, Kakarla, S, Spencer, DM, Dotti, G, Wu, MF, Liu, H, Kenney, S & Gottschalk, S 2011, 'T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies', Blood, vol. 117, no. 16, pp. 4304-4314. https://doi.org/10.1182/blood-2010-04-278218
Shaffer DR, Savoldo B, Yi Z, Chow KKH, Kakarla S, Spencer DM et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011 Apr 21;117(16):4304-4314. https://doi.org/10.1182/blood-2010-04-278218
Shaffer, Donald R. ; Savoldo, Barbara ; Yi, Zhongzhen ; Chow, Kevin K.H. ; Kakarla, Sunitha ; Spencer, David M. ; Dotti, Gianpietro ; Wu, Meng Fen ; Liu, Hao ; Kenney, Shannon ; Gottschalk, Stephen. / T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. In: Blood. 2011 ; Vol. 117, No. 16. pp. 4304-4314.
@article{864677ec90b24d6eb671df4669b8edc6,
title = "T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies",
abstract = "T-cell therapy with genetically modified T cells targeting CD19 or CD20 holds promise for the immunotherapy of hematologic malignancies. These targets, however, are only present on B cell-derived malignancies, and because they are broadly expressed in the hematopoietic system, their targeting may have unwanted consequences. To expand T-cell therapies to hematologic malignancies that are not B cell-derived, we determined whether T cells can be redirected to CD70, an antigen expressed by limited subsets of normal lymphocytes and dendritic cells, but aberrantly expressed by a broad range of hematologic malignancies and some solid tumors. To generate CD70-specific T cells, we constructed a chimeric antigen receptor (CAR) consisting of the CD70 receptor (CD27) fused to the CD3-ξ chain. Stimulation of T cells expressing CD70-specific CARs resulted in CD27 costimulation and recognition of CD70-positive tumor cell lines and primary tumor cells, as shown by IFN-γ and IL-2 secretion and by tumor cell killing. Adoptively transferred CD70-specific T cells induced sustained regression of established murine xenografts. Therefore, CD70-specific T cells may be a promising immunotherapeutic approach for CD70-positive malignancies.",
author = "Shaffer, {Donald R.} and Barbara Savoldo and Zhongzhen Yi and Chow, {Kevin K.H.} and Sunitha Kakarla and Spencer, {David M.} and Gianpietro Dotti and Wu, {Meng Fen} and Hao Liu and Shannon Kenney and Stephen Gottschalk",
year = "2011",
month = "4",
day = "21",
doi = "10.1182/blood-2010-04-278218",
language = "English (US)",
volume = "117",
pages = "4304--4314",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

AU - Shaffer, Donald R.

AU - Savoldo, Barbara

AU - Yi, Zhongzhen

AU - Chow, Kevin K.H.

AU - Kakarla, Sunitha

AU - Spencer, David M.

AU - Dotti, Gianpietro

AU - Wu, Meng Fen

AU - Liu, Hao

AU - Kenney, Shannon

AU - Gottschalk, Stephen

PY - 2011/4/21

Y1 - 2011/4/21

N2 - T-cell therapy with genetically modified T cells targeting CD19 or CD20 holds promise for the immunotherapy of hematologic malignancies. These targets, however, are only present on B cell-derived malignancies, and because they are broadly expressed in the hematopoietic system, their targeting may have unwanted consequences. To expand T-cell therapies to hematologic malignancies that are not B cell-derived, we determined whether T cells can be redirected to CD70, an antigen expressed by limited subsets of normal lymphocytes and dendritic cells, but aberrantly expressed by a broad range of hematologic malignancies and some solid tumors. To generate CD70-specific T cells, we constructed a chimeric antigen receptor (CAR) consisting of the CD70 receptor (CD27) fused to the CD3-ξ chain. Stimulation of T cells expressing CD70-specific CARs resulted in CD27 costimulation and recognition of CD70-positive tumor cell lines and primary tumor cells, as shown by IFN-γ and IL-2 secretion and by tumor cell killing. Adoptively transferred CD70-specific T cells induced sustained regression of established murine xenografts. Therefore, CD70-specific T cells may be a promising immunotherapeutic approach for CD70-positive malignancies.

AB - T-cell therapy with genetically modified T cells targeting CD19 or CD20 holds promise for the immunotherapy of hematologic malignancies. These targets, however, are only present on B cell-derived malignancies, and because they are broadly expressed in the hematopoietic system, their targeting may have unwanted consequences. To expand T-cell therapies to hematologic malignancies that are not B cell-derived, we determined whether T cells can be redirected to CD70, an antigen expressed by limited subsets of normal lymphocytes and dendritic cells, but aberrantly expressed by a broad range of hematologic malignancies and some solid tumors. To generate CD70-specific T cells, we constructed a chimeric antigen receptor (CAR) consisting of the CD70 receptor (CD27) fused to the CD3-ξ chain. Stimulation of T cells expressing CD70-specific CARs resulted in CD27 costimulation and recognition of CD70-positive tumor cell lines and primary tumor cells, as shown by IFN-γ and IL-2 secretion and by tumor cell killing. Adoptively transferred CD70-specific T cells induced sustained regression of established murine xenografts. Therefore, CD70-specific T cells may be a promising immunotherapeutic approach for CD70-positive malignancies.

UR - http://www.scopus.com/inward/record.url?scp=79955970765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955970765&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-04-278218

DO - 10.1182/blood-2010-04-278218

M3 - Article

C2 - 21304103

AN - SCOPUS:79955970765

VL - 117

SP - 4304

EP - 4314

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -